A/Prof Natalie Taylor spearheads Implementation to Impact (i2i), where the focus is on applying implementation science to bridge the gap between evidence and practice.
Our mission is to ensure that the latest research and evidence-based practices are integrated into real-world settings and have a positive impact on people’s lives.
At our core, we believe that everyone deserves access to high-quality, evidence-based care. However, there is often a gap between what we know works and what is implemented in practice. This is where implementation science is crucial.
By using rigorous methods to understand the barriers and facilitators to implementing evidence-based practices, we can develop strategies to promote their adoption and sustainment in real-world settings.
i2i specialises in a range of research interests and expertise:
It can take up to 17 years for research to reach practice, where only 14% eventually reaches the intended beneficiaries (e.g., patients, the community, etc.). One aspect of our Teams expertise involves identifying bottlenecks and gaps to pinpoint where behavioural and system-based implementation support should be targeted.
We are interested in understanding why effective interventions frequently fail to demonstrate impact outside of the research ecosystem. This involves using implementation science frameworks to understand the contextual and behavioural factors affecting implementation success.
Co-designing tailored, targeted, and generalisable strategies for maximum impact
Stakeholder input is crucial to implementation success. We have a range of techniques to co-design evidence based implementation strategies that target key barriers, accounting for context and feasibility.
Improving the efficiency of implementation is key to ensure research innovations are used effectively as quickly as possible. To do this, we need to know more about what works, why, for who, in what contexts, and at what cost. Our research explores implementation processes so that we can specify the active ingredients of implementation success. This means we can use this evidence to reduce the time it takes to solve the next implementation challenge.
Implementation tools are only as good as the extent to which they are used. It's crucial that those with the tacit knowledge and expertise of systems with implementation challenges are equipped with the skills to apply these tools. We provide training, support, and evaluation to professionals through our evidence based program (TRANSLATE).
Every year thousands of Australians suffer unnecessary death or disability from treatable genetic conditions because effective screening is unavailable. Newborn Bloodspot Screening (NBS) of pre-symptomatic infants for treatable genetic conditions is highly effective in reducing death and disability and is one of the top ten public health innovations of the 21st century. Despite recent advances in whole genome and whole exome sequencing, research on these methods suggest clinical, technical, cost, and ethical barriers to their use in expanding NBS. To address these challenges, our team developed, and validated a targeted, adaptive genomic sequencing test for NBS expansion (TAG-NBS), which has been accredited by the National Association of Testing Authorities, Australia for newborn screening. The test sequences a selection of genes, currently 53, for genetic variations that cause treatable genetic conditions. The number of genes in the test can be increased over time, providing a platform for ongoing NBS expansion.
We bring together an internationally recognised, multi-state, multidisciplinary team of experts in translational genomics, newborn screening, clinical genetics, data science, health economics, health policy, clinical psychology, and implementation science, alongside consumer representatives (e.g., Rare Voices Australia), to introduce TAGNBS to the clinical setting. Through a world first clinical effectiveness-implementation trial, our goal is to embed this technology for the early diagnosis of treatable genetic diseases in Australian NBS programs to improve health outcomes.
Medical Research Future Fund (MRFF) Clinical Trials Activity Initiative MRF2022871 2023-2026